Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

James S. Tomlinson, M.D., Ph.D.
James S. Tomlinson, M.D., Ph.D.

Specialty:

Surgical Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Professor, Department of Surgery
Chief of Surgical Oncology, Veterans Affairs Greater Los Angeles Medical Center
Director, Veterans Affairs Greater Los Angeles Cancer Center
Member, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
Greater Los Angeles Veterans Affairs Medical Center

Education:

Fellowship:
Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2003 - 2005
Residency:
General Surgery, UCLA School of Medicine, 1996 - 2003
Internship:
General Surgery, UCLA School of Medicine, 1995 - 1996
Medical Degree:
M.D., University of Pennsylvania School of Medicine, 1995
Degree:
Ph.D., UCLA Department of Molecular and Cellular Pathology, 2009

Certification(s):

Board Certification(s):
Surgery, American Board of Surgery, 2004

Contact Information:

Phone:
(310) 825-6213
Email:

Practice Information:

Clinical Interest(s):
Pancreatic cancers
Liver tumors
Gastrointestinal cancers

Scientific Interest(s):

Dr. James Tomlinson’s research is focused on developing novel engineered antibody fragments as targeting agents against pancreas cancer. He hopes to first translate these antibodies as imaging agents and then secondarily develop these same agents into radioimmunotherapeutics. Additionally, he is involved in collaborations regarding nanoparticle targeting and in vivo click chemistry reactions to enhance targeted therapies.

Selected Cancer-Related Publications:

McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun;14(3):336-47.

Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011 Oct;170(2):169-78. Epub 2011 Apr 20

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging. 2011 Sep 6;2011:834515.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res. 2011 Nov 7;1(1):24.

Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010 Sep;17(9):2312-20. Epub 2010 Apr 27